The Sputnik combination so far yielded better results with Astrazeneca than with Sinopharm

Penelope Canonico

08/01/2021 21:27

• Clarín.com

• Society

Updated 08/01/2021 21:27

The first results of the

vaccine combination

investigation

in the City of Buenos Aires have so far shown that the

Sputnik V - Astrazeneca

option

has a better performance than Sputnik V - Sinopharm

, according to an advance that

Clarín was

able to access

.

These are preliminary results and sources from the Buenos Aires Ministry of Health

do not rule out that Sinopharm can also be used

as a second dose in the absence of the Russian.

To have more results you will have to wait a few days.

The study carried out by the Buenos Aires Ministry of Health would show that in the combination of platforms, the one that offers the greatest effect is that of Astrazeneca with Sputnik, according to health sources told Clarín.

The benefit is the potential of both vaccines to

generate a higher percentage of cells of the immune system

.

On the other hand, the Sinopharm one did not prove to bring many benefits in terms of the union with the Gamaleya Institute.

However, among specialists from the Argentine Society of Infectology (SAI) there is an expectation that the

best result of the combination with Sputnik will be with a messenger RNA vaccine

(Pfizer or Moderna). As

Clarín

learned

, the final results of the City study with the Modern vaccine combination will be available in one or two weeks. The forecast is that Moderna could provide a greater amplification of the immune response. 

The trial, which began with 180 volunteers on July 7, yielded encouraging results and ran optimally in terms of safety parameters. According to sources that collaborated in the immunological determinations and in the absence of the second dose of Sputnik V, in

two weeks this heterologous combination could be opened to the entire population

in order to complete the two-dose schedule. But, it will be the health authority of the Nation who makes the decision.

Only in the Capital there are 741,323 people vaccinated with component 1 of the Russian immunizer.

Of these, 197,778 completed the two-dose

schedule

, so

543,545 await the assignment of a new shift.

Of these, some 150,000 have already met the 12-week deadline stipulated in the strategy of applying one dose to the largest number of people.

But that methodology changed and it was decided to

accelerate vaccination with second doses

to add protection against the threat of the Delta variant.

Nationwide the number grows to almost 7 million people who received one dose and are waiting for the second.

Given the deficiency of component 2 of Sputnik V, the Province of Buenos Aires also carried out a safety study on the combinations of the Sputnik V vaccines with Sinopharm and with Astrazeneca.

The tests did not report

any serious adverse events.

MG

Look also

The Government plans to continue vaccinating adolescents without comorbidities with the doses of Moderna

The City adds Moderna's vaccine to its study to replace component 2 of Sputnik V

They ask that those who received a dose of Sputnik V restart their immunization with another vaccine